Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.
Oncotarget | February 12, 2018
Papillary thyroid carcinoma (PTC) is the most common type of cancer of the thyroid, which is the butterfly-shaped gland at the base of the neck. Treatment of PTC tumors has been difficult because people often develop resistance to the drugs used. Researchers from Harvard Medical School and the University of Parma in Parma, Italy recently ran a study in search of a combinatorial approach that would expand known treatment options. The study is featured in Oncotarget, Advanced Publications, entitled “Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma… continue reading »
Oncotarget | February 6, 2018
A new study shows that consuming decaffeinated green tea does not modify body weight or abdominal obesity in men at high risk for prostate cancer. The findings, which were published in Oncotarget, demonstrate that that men at high risk for prostate cancer should not resort to ineffective measures such as taking supplements of green tea to reduce biomarkers of obesity. Medical evidence suggests that men who are obese are more likely to develop prostate cancer, and because more than one third of the U.S. population is obese, there is a need for interventions that can reduce obesity in populations at… continue reading »


Which combinations of anti-cancer drugs would be the most effective in treating colon cancer?

OncotargetFebruary 6, 2018
Until a few decades ago, there was only one main drug available to treat colon cancer. Now, however, there are several standard therapies as well as newer targeted drugs that are frequently used in combination. Although it’s natural to assume that combinations of anti-cancer drugs would have a greater effect than single drugs alone, there are some cases where combinations of anti-cancer drugs are not actually effective. By conducting an analysis of the survival effects of drug combinations, researchers may now have a better picture of which of these combinations are likely to be the most successful. Their study results… continue reading »
Oncotarget | February 6, 2018
Drug pricing is a big issue in the news, and there is continued controversy surrounding the major differences in patented cancer drug prices around the world.
Oncotarget | February 6, 2018
In a study published in Oncotarget, researchers from Sweden investigated the role of a common virus known as human cytomegalovirus (HCMV) to better understand how HCMV influences the molecular mechanisms involved in cancer. HCMV is the largest member of the herpes virus family. Once it infects a person, it stays in their body for life and can reactivate. Most people don’t show signs or symptoms of the virus because the immune system normally keeps the virus in check. But in people with compromised immune systems, the virus can cause life-threatening disease. The virus has been found to be active within… continue reading »